ABSTRACT
OBJECTIVES: The aim of this study was to evaluate the pharmacoeconomic profile in Italy of preoperative treatment with ulipristal acetate at the dose of 5â¯mg/day for 13 weeks in comparison with placebo prior to surgical management of symptomatic uterine fibroids. STUDY DESIGN: The pharmacoeconomic analysis was based on the calculation of incremental cost-effectiveness ratio (ICER). Effectiveness data were derived from the randomized-controlled trial PEARL-1, whilst costs data were retrieved from the published literature. A Markov model was employed to simulate the pattern of costs and two univariate sensitivity analyses tested the robustness of the results. RESULTS: In comparison with placebo, ulipristal acetate 5â¯mg for presurgical therapy was estimated to be associated with an incremental cost of 351 per patient. Costs per patient were 3836 for ulipristal acetate vs 3485 for placebo. The incremental effectiveness was 0.01931 QALYs per patient (around 7 quality-adjusted days per patient). Hence, the cost effectiveness ratio was calculated to be 18,177 per QALY gained. CONCLUSIONS: Preoperative use of ulipristal acetate 5â¯mg in patients with uterine fibroids has a favourable pharmacoeconomic profile.
Subject(s)
Contraceptives, Oral, Hormonal/therapeutic use , Leiomyoma/drug therapy , Leiomyomatosis/drug therapy , Models, Economic , Norpregnadienes/therapeutic use , Preoperative Care , Uterine Neoplasms/drug therapy , Adult , Cohort Studies , Combined Modality Therapy/adverse effects , Combined Modality Therapy/economics , Contraceptives, Oral, Hormonal/adverse effects , Contraceptives, Oral, Hormonal/economics , Cost-Benefit Analysis , Female , Health Care Costs , Humans , Hysterectomy/adverse effects , Hysterectomy/economics , Italy , Leiomyoma/economics , Leiomyoma/physiopathology , Leiomyoma/surgery , Leiomyomatosis/economics , Leiomyomatosis/physiopathology , Leiomyomatosis/surgery , Norpregnadienes/adverse effects , Norpregnadienes/economics , Preoperative Care/adverse effects , Preoperative Care/economics , Quality of Life , Randomized Controlled Trials as Topic , Tumor Burden/drug effects , Uterine Artery Embolization/adverse effects , Uterine Artery Embolization/economics , Uterine Hemorrhage/economics , Uterine Hemorrhage/etiology , Uterine Hemorrhage/prevention & control , Uterine Hemorrhage/therapy , Uterine Myomectomy/adverse effects , Uterine Myomectomy/economics , Uterine Neoplasms/economics , Uterine Neoplasms/physiopathology , Uterine Neoplasms/surgerySubject(s)
Evidence-Based Medicine , Leiomyoma/therapy , Leiomyomatosis/therapy , Uterine Neoplasms/therapy , Combined Modality Therapy/adverse effects , Combined Modality Therapy/economics , Cost of Illness , Female , Genetic Predisposition to Disease , Genetic Variation , Health Care Costs , Health Services Accessibility , Humans , Infertility, Female/etiology , Infertility, Female/prevention & control , Leiomyoma/economics , Leiomyoma/genetics , Leiomyoma/physiopathology , Leiomyomatosis/economics , Leiomyomatosis/genetics , Leiomyomatosis/physiopathology , Practice Guidelines as Topic , Quality of Life , Uterine Neoplasms/economics , Uterine Neoplasms/genetics , Uterine Neoplasms/physiopathologySubject(s)
Leiomyoma/therapy , Leiomyomatosis/therapy , Patient-Centered Care , Practice Guidelines as Topic , Uterine Neoplasms/therapy , Academies and Institutes , Boston , Combined Modality Therapy/economics , Combined Modality Therapy/trends , Female , Health Care Costs , Humans , Leiomyoma/economics , Leiomyomatosis/economics , National Academies of Science, Engineering, and Medicine, U.S., Health and Medicine Division , Patient Advocacy , Patient-Centered Care/economics , Patient-Centered Care/trends , Quality of Health Care/economics , Quality of Health Care/trends , United States , Uterine Neoplasms/economicsABSTRACT
OBJECTIVE: The purpose of this study was to estimate the total annual societal cost of uterine fibroid tumors in the United States, based on direct and indirect costs that include associated obstetric complications. STUDY DESIGN: A systematic review of the literature was conducted to estimate the number of women who seek treatment for symptomatic fibroid tumors annually, the costs of medical and surgical treatment, the amount of work time lost, and obstetric complications that are attributable to fibroid tumors. Total annual costs were converted to 2010 US dollars. A sensitivity analysis was performed. RESULTS: The estimated annual direct costs (surgery, hospital admissions, outpatient visits, and medications) were $4.1-9.4 billion. Estimated lost work-hour costs ranged from $1.55-17.2 billion annually. Obstetric outcomes that were attributed to fibroid tumors resulted in a cost of $238 million to $7.76 billion annually. Uterine fibroid tumors were estimated to cost the United States $5.9-34.4 billion annually. CONCLUSION: Obstetric complications that are associated with fibroid tumors contributed significantly to their economic burden. Lost work-hour costs may account for the largest proportion of societal costs because of fibroid tumors.
Subject(s)
Leiomyomatosis/economics , Uterine Neoplasms/economics , Absenteeism , Adult , Cost of Illness , Female , Health Care Costs , Humans , Middle Aged , United States/epidemiologyABSTRACT
STUDY OBJECTIVE: The objective of our study was to quantify the rate, type, and cost of interventions for uterine myomas to payers in Germany, France, and England. DESIGN: Computations using data from national hospital activity databases. DESIGN CLASSIFICATION: II-3. SETTING: Hospital admissions in Germany, France, and England. PATIENTS: Women admitted for a surgical or radiologic intervention for uterine myomas. INTERVENTIONS: Surgical or radiologic interventions for uterine myomas. MEASUREMENTS AND MAIN RESULTS: We identified the number and type of hospital admissions involving surgical or radiologic interventions for uterine myomas, through the analysis of national hospital activity databases from each country. We calculated the costs of these hospitalizations to payers in these countries using the diagnosis-related group reimbursement rates. In 2005, the number (rate) of hospital admissions involving interventions for uterine myomas was 64 299 (1.53/1000 women) in Germany, 37 787 (1.17/1000 women) in France, and 18 274 (0.71/1000 women) in England. The annual costs of these interventions to payers were euro212 313 090 in Germany, euro73 278 270 in France (excluding surgeon and anesthetist fees for interventions in the private sector), and euro52 674 672 in England. The percentage of interventions for uterine myomas that included a hysterectomy was 84.9% in Germany, 59.7% in France, and 64.1% in England. CONCLUSION: The number of admissions and costs associated with interventions for uterine myomas are substantial in the 3 European countries studied. Hysterectomy is the most frequent surgical intervention used to treat uterine myomas. The results in this article provide useful information for policy makers wishing to evaluate the cost effectiveness and budget impact of new, less invasive interventions.
Subject(s)
Gynecologic Surgical Procedures/statistics & numerical data , Leiomyomatosis/epidemiology , Leiomyomatosis/surgery , Minimally Invasive Surgical Procedures/statistics & numerical data , Costs and Cost Analysis , Europe/epidemiology , Female , Gynecologic Surgical Procedures/economics , Humans , Leiomyomatosis/economics , Minimally Invasive Surgical Procedures/economicsABSTRACT
PURPOSE: To compare health resource use and medical costs in patients with uterine leiomyomas treated with hysterectomy, myomectomy, or uterine artery embolization (UAE). MATERIALS AND METHODS: Patients who underwent hysterectomy, myomectomy, or UAE for leiomyomas were identified from a nationally representative private payer claims database based on their diagnosis and procedure codes. The study included patients with no prior hysterectomy, myomectomy, or UAE and no previous diagnosis of gynecologic cancer. Health resource use and medical costs were evaluated over a period of 12 months. RESULTS: The study included 2,836 hysterectomy, 704 myomectomy, and 125 UAE patients. Average patient ages were 46 years for hysterectomy, 38 years for myomectomy, and 45 years for UAE (P < .001). Median UAE procedure costs were $5,968, compared with $7,299 for myomectomy (P = .031) and $7,707 for hysterectomy (P < .001). Median total 12-month payer costs were not significantly different among the three procedures ($10,519 for UAE vs $9,652 for myomectomy [P = .372] and $10,044 for hysterectomy [P = .813]). There were no differences in overall hospital admissions or emergency room visits after the procedures. Patients who underwent UAE had greater fibroid-related hospital and physician office use beyond 30 days after treatment (P < .001). During this period, 65.6% of patients treated with UAE had at least one imaging study, versus 37.1% of those treated with myomectomy (P < .001) and 14.1% of those treated with hysterectomy (P < .001). CONCLUSIONS: Procedure costs were significantly lower for UAE versus myomectomy and hysterectomy, but there was no difference in total 12-month payer costs. Postprocedural imaging appears to be a factor in total UAE costs. Further research is needed to better understand the role of imaging studies after UAE.